We Exist to Make Advanced Medicine Universal
Ablatotech was founded on a conviction: the most transformative medicine in human history should not be reserved for the wealthiest fraction of humanity.
Today, a cancer patient in sub-Saharan Africa has virtually no access to immunotherapy. A child in rural South Asia with an undiagnosed fever cannot receive targeted treatment because no laboratory exists to identify the pathogen. A family in Latin America facing a rare genetic disease has no treatment at any price.
We are building the technology to change all of this — not incrementally, but fundamentally. Our living-medicine platform delivers the most advanced immunological therapies in an oral capsule, manufactured at commodity scale, stable at room temperature, and priced for global access.
Engineered for Every Patient on Earth
Dr. George Ekema
Dr. George Ekema is the inventor behind Ablatotech's foundational technology — a universal platform for preventing and treating disease with transformed microbes. This body of innovation represents years of research into how engineered microorganisms can be programmed as living therapeutic agents.
Dr. George Ekema's vision extends far beyond any single disease. The goal is a platform technology that can be adapted to prevent and treat virtually any disease — from the most common cancers to the rarest genetic conditions — and to deliver these therapies in a form that reaches every patient on Earth, including the billions who today have access to none of modern medicine's most powerful tools.
Under Dr. George Ekema's leadership, Ablatotech has built a comprehensive intellectual property portfolio, an AI-powered drug discovery engine, and active therapeutic programs spanning seven disease categories — a scope that is unprecedented for a biotechnology platform at this stage.
What Drives Every Decision at Ablatotech
Science Without Compromise
Every therapeutic approach we pursue is grounded in rigorous scientific methodology. Our AI engine processes hundreds of thousands of data points per analysis. Our safety architecture is validated to one-in-ten-billion precision. We do not cut corners.
Designed for the Hardest Cases First
We do not design for wealthy markets and hope to trickle down. We design for the village clinic with no electricity, the patient with no hospital access, the family with no insurance. When medicine works there, it works everywhere.
Eight Billion Patients
We believe healthcare breakthroughs should benefit all of humanity. Our oral, ambient-stable, sub-dollar therapeutics are engineered from the ground up for global deployment — including in the most resource-constrained settings.
AI-Native From Day One
Artificial intelligence is not an afterthought at Ablatotech. Our drug discovery engine, literature intelligence system, and regulatory strategy are all AI-driven — compressing years of R&D into days and ensuring every decision is informed by the full body of biomedical knowledge.
Intellectual Property Fortress
Our innovations are protected by a comprehensive intellectual property portfolio spanning the entire platform — from organism engineering to manufacturing processes, safety architecture to delivery systems. We build to own the future.
Speed Is a Moral Imperative
People are dying from diseases we can prevent. Every month of delay is measured in lives lost. Our AI-accelerated pipeline, automated regulatory intelligence, and commodity-scale manufacturing are all designed for one thing: getting medicine to patients faster.